论文信息 - Prognostication of HCC under sorafenib: Is it always possible? - 字舞流文

Prognostication of HCC under sorafenib: Is it always possible?

We have read with great interest the study of Tim Labeur et al1 regarding a new prognostic model namely PROSASH-II for the outcome prediction of hepatocellular carcinoma (HCC) patients under sorafenib treatment.

J. Raoul | M. Bourlière | G. Pénaranda | X. Adhoute | M. Bourliere

[1] T. Meyer,et al. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[2] J. Raoul,et al. Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis , 2019, Liver Cancer.

[3] M. Kudo,et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. , 2018, Cancer treatment reviews.

[4] J. Bruix,et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.

[5] J. Blanc,et al. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C results from a French multicenter study , 2015, European journal of gastroenterology & hepatology.